Top 50 Medical VC Funds & Investors in Austria (September 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
XISTA Science Ventures
VC Fund
|
8 | Austria, Germany, France | Seed, Pre-Seed, Series A | Biotechnology, Medical, Software | $548k–$20M |
|
Speedinvest
VC Fund
|
6 | United Kingdom, Germany, Austria | Seed, Series A, Pre-Seed | Software, FinTech, Financial Services | $411k–$33M |
|
xista science ventures
VC Fund
|
5 | Austria, Slovenia | Seed, Pre-Seed, Series A | Biotechnology, Medical, Software | $552k–$20M |
|
APEX Ventures
VC Fund
|
4 | Germany, United Kingdom, Austria | Seed, Series A, Pre-Seed | Artificial Intelligence, Software, Health Care | $552k–$22M |
|
SOSV
VC Fund
|
4 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
austria Wirtschaftsservice (aws)
VC Fund
|
3 | Austria, Belgium | Seed, Grant, Pre-Seed | Software, Information Technology, Artificial Intelligence | $62k–$2.7M |
|
The Austrian Research Promotion Agency (FFG)
VC Fund
|
3 | Austria, United States, Belgium | Grant, Seed, Pre-Seed | Software, Artificial Intelligence, Medical | $67k–$2.8M |
|
Austria Wirtschaftsservice (AWS)
VC Fund
|
3 | Austria, Philippines | Seed, Pre-Seed, Grant | Medical, Machine Learning, Artificial Intelligence | $510k–$2.3M |
|
SquareOne Venture Capital
VC Fund
|
3 | Germany, United States, Poland | Seed, Series A, Series B | Software, Artificial Intelligence, SaaS | $1M–$30M |
|
MassMutual Ventures
VC Fund
|
3 | United States, India, Singapore | Series A, Series B, Seed | Software, Financial Services, Information Technology | $2.7M–$50M |
|
tecnet equity
VC Fund
|
3 | Austria | Seed, Series A | Software, Biotechnology, Artificial Intelligence | $400k–$20M |
|
Cherry Ventures
VC Fund
|
3 | Germany, United Kingdom, United States | Seed, Series A, Series B | Software, Information Technology, Financial Services | $1.9M–$117M |
|
eQventure
VC Fund
|
2 | Austria, Germany, Switzerland | Seed, Series A, Series B | Software, Information Technology, Automotive | $540k–$13M |
|
SkyGene
VC Fund
|
2 | Austria | Venture - Series Unknown | Medical, Health Care, Biotechnology | |
|
Kinled Holding
VC Fund
|
2 | United Kingdom, United States, Switzerland | Seed, Series A | Biotechnology, Health Care, Software | $594k–$40M |
|
FREE VALLEY HOLDINGS LIMITED
VC Fund
|
2 | Austria | Seed, Series A | Medical, Analytics, Health Diagnostics | |
|
Ligand Pharmaceuticals
VC Fund
|
2 | United States, Austria, Denmark | Post-IPO Debt, Corporate Round, Post-IPO Equity | Biotechnology, Medical, Health Care | $3M–$90M |
|
aws Gründungsfonds
VC Fund
|
2 | Austria, Germany, United States | Seed, Series A | Software, SaaS, Information Technology | $1.1M–$11M |
|
bmp Ventures
VC Fund
|
2 | Germany, United States, Austria | Seed, Series A | Software, Information Technology, Manufacturing | $165k–$5.9M |
|
LANA Ventures
VC Fund
|
2 | Austria, Germany | Seed, Pre-Seed | Health Care, Medical, Software | $2.8M–$6.5M |
|
HV Capital
VC Fund
|
2 | Germany, United Kingdom, United States | Series A, Seed, Series B | E-Commerce, Software, Internet | $1.5M–$80M |
|
MMC Ventures
VC Fund
|
2 | United Kingdom, United States, France | Seed, Series A, Series B | Software, Artificial Intelligence, Machine Learning | $1.4M–$54M |
|
MIG Capital
VC Fund
|
2 | Germany, France, Austria | Series A, Series B, Seed | Biotechnology, Health Care, Software | $1.3M–$60M |
|
West Asia Investment Partners S.a.r.l.
VC Fund
|
2 | Austria | Seed, Series A | Medical, Analytics, Health Diagnostics | |
|
Medicus Ltd
VC Fund
|
2 | Austria | Angel, Series A | Medical, Analytics, Health Diagnostics | |
|
VP Venture Partners
VC Fund
|
2 | Austria, Switzerland | Seed | Medical, Health Diagnostics, Internet | $3M–$6.9M |
|
Peak Pride
VC Fund
|
2 | Austria, Germany | Seed, Series A, Pre-Seed | Health Care, Medical, Health Diagnostics | $165k–$6.5M |
|
Wellcome Trust
VC Fund
|
1 | United States, United Kingdom, France | Grant, Series C | Biotechnology, Health Care, Medical | $1.6M–$127M |
|
IBG Beteiligungsgesellschaft Sachsen-Anhalt
VC Fund
|
1 | Germany, Austria | Seed, Venture - Series Unknown, Series A | Medical Device, Software, Electronics | $1.3M–$13M |
|
Arax Capital Partners
VC Fund
|
1 | Austria, United States | Seed, Venture - Series Unknown, Series A | Biotechnology, Software, Health Care | $600k–$10M |
|
NEOÏ S.à.r.l
VC Fund
|
1 | Austria | Series A | Medical, Analytics, Health Diagnostics | |
|
EMBL Ventures
VC Fund
|
1 | Germany, Austria, Ireland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.9M–$70M |
|
IPO Beteiligungs-Management
VC Fund
|
1 | Austria | Series B | Sensor, Medical, Wireless | |
|
red-stars.com
VC Fund
|
1 | Austria, Germany | Seed, Pre-Seed | Software, Biotechnology, Telecommunications | $1.8M–$4.4M |
|
FCPG Affi
VC Fund
|
1 | Austria | Venture - Series Unknown | Medical, Biotechnology, Pharmaceutical | |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
1 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
Novartis Venture Fund
VC Fund
|
1 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$120M |
|
redalpine
VC Fund
|
1 | Germany, Switzerland, United Kingdom | Seed, Series A, Series B | Biotechnology, Health Care, Software | $1.6M–$59M |
|
Santo Holding
VC Fund
|
1 | Germany, Austria | Venture - Series Unknown, Series B, Series C | Biotechnology, Energy, Medical | $7.7M–$10M |
|
Biopart
VC Fund
|
1 | Austria | Series A | Medical, Analytics, Health Diagnostics | |
|
Baxter International
VC Fund
|
1 | United States, Canada, Austria | Seed, Series B, Series C | Health Care, Biotechnology, Medical | $238k–$25M |
|
SquareOne
VC Fund
|
1 | Germany, United States, Poland | Seed, Series A | Software, SaaS, E-Commerce | $329k–$17M |
|
IT-Farm
VC Fund
|
1 | United States, Japan, Germany | Seed, Series A | Software, Health Care, Medical | $1.8M–$20M |
|
Revere Partners
VC Fund
|
1 | United States, The Netherlands, Austria | Seed, Pre-Seed, Series A | Health Care, Dental, Medical | $1M–$4.5M |
|
Techno Venture Management
VC Fund
|
1 | United States, Germany, United Kingdom | Series B, Series A | Biotechnology, Health Care, Pharmaceutical | $4.7M–$44M |
|
MMV Europe & Asia-Pacific
VC Fund
|
1 | Singapore, India, United States | Series A, Seed, Series B | Financial Services, FinTech, Health Care | $2.4M–$65M |
|
i&i Biotech Fund
VC Fund
|
1 | Czech Republic, India, Spain | Seed, Series A | Biotechnology, Health Care, Medical | |
|
TBA Network
VC Fund
|
1 | Austria, Italy | Seed | Apps, Medical, mHealth | |
|
Lead Ventures
VC Fund
|
1 | Hungary, United Kingdom, Croatia | Series A, Seed, Series B | Software, SaaS, Artificial Intelligence | |
|
Tensor Ventures
VC Fund
|
1 | Czech Republic, United States, United Kingdom | Pre-Seed, Seed | Artificial Intelligence, Information Technology, Machine Learning | |
| Access all 113 VC funds in Austria Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
We invest in deep tech startups and academic spin-offs with a strong innovation based on science, engineering and technology. We invest as lead investor in pre-seed and seed stages and have the ability to follow on in later rounds. We understand the needs of science and tech based startups and offer tailored support for entrepreneurs. We areembedded in the venture capital scene, yet understand the language of science and the world of research. Thanks to our diverse team, our expertise and experience in technology, entrepreneurship, finance, legal, IP, and strategic consulting will support your startup right from the start.
Show more...Investment focus
- Industry: Biotechnology, Medical, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Austria, Germany, France
Investor stats
- Total investments: 47
- Round size: Seed $1.8M–$6.9M; Pre-Seed $548k–$1.7M; Series A $5.7M–$20M
- Lead/follow: 57% lead, 43% follow
Portfolio highlights
- Rivus Batteries — Rivus is a start-up that serves as the commercialization platform for the aqueous organic flow battery technology.
- Ora Computing — We make AI models smaller, faster, and more efficient.
- Epitome Therapeutics — Epitome Therapeutics is an early-stage biotechnology company developing CADENCE, a next-generation epigenome editing platform for precise, durable, and context-dependent control of gene expression without altering the underlying DNA sequence, with the aim of establishing a new therapeutic modality for diseases driven by dysregulated gene activity.
Speedinvest is a globally active European venture capital firm built on a simple belief: many move more. From six offices across EMEA, our sector-focused investment teams back relentless founders from pre–Seed to Growth with long-term conviction, providing day-one access to our global network of corporate customers, experts, industry leaders, andtop-tier follow-on investors to scale smarter and faster. Building lasting companies like Bitpanda (Austria), Moove (Nigeria), Gigs (U.S.), Tide (UK), ARX Robotics (Germany), Wayflyer (Ireland), GoStudent (Austria), Seqera Labs (Spain), and Cylib (Germany) — together. Big ideas may start with one. But scaling and winning take The Power of More.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, Germany, Austria
Investor stats
- Total investments: 662
- Round size: Seed $798k–$7.9M; Pre-Seed $411k–$3.8M; Series A $4.1M–$33M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $372M in 2022
Portfolio highlights
- Findery — Find and leave notes anywhere in the world, discover local knowledge, hidden secrets, and exciting stories. Share your travel knowledge, geoblog, or local news!
- GAMINSIDE — GAMINSIDE revolutionizes your relationship with your customers. As European full service provider, we deliver the complete package with solutions, services and software for gamified loyalty that is tailor-made and unique to your products, brands and customers. Integrate the best ideas from gamification and customer loyalty in your business areato exceed your commercial targets with GAMINSIDE.
- Polaron — Material Design. Supercharged with AI.
We invest in deep tech startups and academic spin-offs with a strong innovation based on science, engineering and technology. We invest as lead investor in pre-seed and seed stages and have the ability to follow on in later rounds. We understand the needs of science and tech based startups and offer tailored support for entrepreneurs. We areembedded in the venture capital scene, yet understand the language of science and the world of research. Thanks to our diverse team, our expertise and experience in technology, entrepreneurship, finance, legal, IP, and strategic consulting will support your startup right from the start.
Show more...Investment focus
- Industry: Biotechnology, Medical, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Austria, Slovenia
Investor stats
- Total investments: 22
- Round size: Seed $1.8M–$7.3M; Pre-Seed $552k–$1.5M; Series A $5.7M–$20M
- Lead/follow: 64% lead, 36% follow
Portfolio highlights
- subdron — subdron turns the seabed from a blind spot into a monitored domain.
- infrared.city — Redefine environmental simulations. Our bespoke AI models revolutionise performative design, slashing time, cost, and complexity. Access cutting-edge services effortlessly because innovation should be for everyone
- VALANX Biotech — VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.
APEX Ventures is a deep-tech and medical focused venture capital firm, run by founders with complimentary backgrounds driven by the same mission.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United Kingdom, Austria
Investor stats
- Total investments: 53
- Round size: Seed $1.4M–$8M; Pre-Seed $552k–$9.1M; Series A $2.4M–$22M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- GEMESYS — Gemesys creates a chip that functions similarly to the human brain in order to overcome processing constraints and empower AI with the hardware it needs to complete its destiny
- HyperHeat — HyperHeat is building a cutting-edge, all-electric heating solution designed to reach temperatures of up to 2,000°C. Using renewable electricity HyperHeat is providing an efficient alternative to fossil fuel combustion. With an efficiency rate of up to 98%, HyperHeat is ideal for retrofitting industrial processes, enabling significant CO2reductions across industries like steel, cement, and chemicals. The scalable technology offers a cost-efficient approach to decarbonizing thermal processes, with a potential to reduce global CO2 emissions by over 4.5 gigatons annually.
- TriLite Technologies — The world's smallest projection displays from TriLite take laser beam scanning technology to the next level, for augmented vision as light as the eyewear of today.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
The Austrian Economic Service mbH (aws) is the promotional bank of the Federal Government.The aws SME fund is the largest Austrian Fund for silent corporate investments, but also providers of equity. Founded in late 2009 by the Austrian Economic Service mbH (aws) - the Development Bank of the Federal - he has a term until 31/12/2025.The fund is currently endowed with EUR 80 million and participates in medium-sized companies and brings with it a fresh capital to develop new products or processes, for sales development to international expansion.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Grant, Pre-Seed
- Geography: Austria, Belgium
Investor stats
- Total investments: 76
- Round size: Seed $439k–$2.7M; Grant $62k–$2.3M; Pre-Seed $195k–$1.6M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $92M in 2013
Portfolio highlights
- Repentium — We strive to create
- Graph Therapeutics — Graph Therapeutics - precision immunology
- Epitome Therapeutics — Epitome Therapeutics is an early-stage biotechnology company developing CADENCE, a next-generation epigenome editing platform for precise, durable, and context-dependent control of gene expression without altering the underlying DNA sequence, with the aim of establishing a new therapeutic modality for diseases driven by dysregulated gene activity.
The Austrian Research Promotion Agency (FFG) is the national funding agency for industrial research and development in Austria. As a "one-stop shop" offering a diversified and targeted programme portfolio, the FFG gives Austrian businesses and research facilities quick and uncomplicated access to research funding.The FFG was foundedon 1 September 2004 (pursuant to the FFG Act on establishing a research promotion agency, Federal Law Gazette I No. 73/2004). The FFG is wholly owned by the Republic of Austria, represented by the Federal Ministry for Transport, Innovation and Technology (bmvit) and the Federal Ministry of Science, Research and Economy (BMWFW). As a provider of funding services, however, the FFG also works for other national and international institutions.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Medical
- Stage:Grant, Seed, Pre-Seed
- Geography: Austria, United States, Belgium
Investor stats
- Total investments: 75
- Round size: Seed $745k–$2.8M; Grant $67k–$2.5M; Pre-Seed $480k–$1.9M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Another Earth — Another Earth is building an AI-powered simulation and synthetic data platform for Earth Observation. As our planet changes, AI models need scalable, high-quality training data to keep pace. Another Earth provides synthetic data, scenario simulations and predictions required to accelerate AI development, and enable faster, smarterdecision-making—enabling smarter decisions for a more resilient world.
- Graph Therapeutics — Graph Therapeutics - precision immunology
- Epitome Therapeutics — Epitome Therapeutics is an early-stage biotechnology company developing CADENCE, a next-generation epigenome editing platform for precise, durable, and context-dependent control of gene expression without altering the underlying DNA sequence, with the aim of establishing a new therapeutic modality for diseases driven by dysregulated gene activity.
Austria Wirtschaftsservice is an investment firm.
Show more...Investment focus
- Industry: Medical, Machine Learning, Artificial Intelligence
- Stage:Seed, Pre-Seed, Grant
- Geography: Austria, Philippines
Investor stats
- Total investments: 8
- Round size: Seed $751k–$2.3M; Pre-Seed $510k–$1.6M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- S2data — Revolutioniere deine Lieferkette mit intelligenter Logistik. Effiziente Transporte durch bahnbrechende Algorithmen & einzigartige Software.
- Syntropic Medical — Syntropic is a medical device company that develops novel technologies that helps for the treatment of psychiatric diseases and the improvement of cognitive abilities.
- Cycuria Therapeutics — While new therapies, such as FLT3 inhibitors and venetoclax-based regimens, have improved initial response rates, durable remissions and long-term survival
We invest in B2B tech entrepreneurs who are obsessed with solving complex problems in huge markets at pre-seed and seed stage
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Series A, Series B
- Geography: Germany, United States, Poland
Investor stats
- Total investments: 78
- Round size: Seed $1M–$7.4M; Series A $3.2M–$20M; Series B $5M–$30M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $84M in 2022
Portfolio highlights
- Ultralytics — Simpler. Smarter. Further.
- Flinn — We are driven to impact the health of millions of people around the globe by enabling medical companies to launch and operate products more efficiently. To make this vision come true, we established a customer-centric, experimentation-driven product development approach.
- Graph Therapeutics — Graph Therapeutics - precision immunology
MMV is a multistage, global venture capital firm investing in enterprise software, cybersecurity, financial technology, and digital health companies. We help accelerate the growth of the companies we partner with by providing capital, connections and advice.
Show more...Investment focus
- Industry: Software, Financial Services, Information Technology
- Stage:Series A, Series B, Seed
- Geography: United States, India, Singapore
Investor stats
- Total investments: 160
- Round size: Seed $2.7M–$11M; Series A $5M–$23M; Series B $7M–$50M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fresh fund, raised $150M in 2026
Portfolio highlights
- Versana — Centralized, real-time digital agent data unlocks end-to-end solutions across the $8T broadly syndicated loan and private credit markets.
- AGent Energy — AGent Energy operates a hardware and software platform that connects commercial, industrial, and institutional backup generators and other distributed energy resources to electricity markets. The company installs onsite equipment and software, monitors generator condition and utilization, and manages participation in demand-response and other gridprograms. Its platform supports remote dispatch, operational alerts, anomaly detection, compliance processes, and diagnostic data for facilities such as hospitals, manufacturers, data centers, universities, agricultural sites, retailers, and water infrastructure operators. AGent Energy shares market proceeds with participating facility owners while maintaining generator availability for backup use.
- EduFund — EduFund is India's leading education finance platform, helping parents plan, save, and pay for their child's higher education, in India or abroad. Co-founded in 2020 by Eela Dubey and Arindam Sengupta, EduFund was built on a simple conviction: most Indian families focus intensely on academic preparation for college and almost entirelyignore the financial side until it's too late. Eela Dubey, Co-founder and CEO, is a NYU graduate with a background in hedge funds on Wall Street. Arindam Sengupta, Co-founder, is a Princeton University alumnus with experience at Citadel and Reliance Capital. Together, they built EduFund to close the gap between being academically ready and financially ready for higher education. The platform offers a full suite of education finance tools, including mutual fund SIPs, fixed deposits, digital gold, and term insurance, alongside education loans, scholarship discovery, and end-to-end admissions support. Its AI-powered college cost calculator, Taara, gives parents inflation-adjusted cost estimates across 3,000+ colleges in 19+ countries in seconds, factoring in tuition, living costs, and currency risk. EduFund started out as a B2C app for consumers. EduFund's B2B platform, Vittam, serves to scale the same mission through India's MFD ecosystem, enabling wealth distributors to offer their clients a broader suite of financial products, from education loans and GIFT City funds to EB-5 global investment products and international health insurance. EduFund has served 250,000+ families and built a partner network of 40+ asset management firms and 15+ lending institutions, along with over 300 MFDs and IFA's through it's B2B vertical, Vittam. EduFund has raised $12 million in total funding, including a $6 million Series A led by Cercano Management and MassMutual Ventures. The company is also supported by angel investors.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!tecnet equity is an Austrian venture capital fund investing in innovative high-tech companies with potential for significant growth.
Show more...Investment focus
- Industry: Software, Biotechnology, Artificial Intelligence
- Stage:Seed, Series A
- Geography: Austria
Investor stats
- Total investments: 74
- Round size: Seed $400k–$2.5M; Series A $557k–$20M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $33M in 2009
Portfolio highlights
- PROPCORN AI — At PROPCORN, our goal is to harness the power of AI to automatically unlock the full real estate building potential of our customers, enabling them to make faster and more accurate decisions in real-time.
- deepentix — Deepentix provides a graph-as-a-service platform that converts unstructured documents into verifiable claim graphs. Its software extracts semantic claims, qualifiers, constraints, and confidence information, then links entities to domain ontologies. The Claim Graph API supports natural-language and API-based queries with paragraph-level citations,conflict flags, policy checks, and provenance paths. Private extractors use domain-tuned small language models for organization-specific templates and terminology. Deepentix also offers hosted and on-premises graph deployments that can integrate with systems such as electronic laboratory notebooks, laboratory information management systems, claims systems, and chat copilots. The platform is intended for regulated workflows in life sciences, insurance, legal and regulatory work, and climate and ESG analysis where document-based decisions require traceability and audit records.
- VALANX Biotech — VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.
Cherry Ventures is an early-stage venture capital firm led by a team of entrepreneurs with experience building fast-scaling companies such as Zalando and Spotify. The firm backs Europe's boldest founders, usually as their first institutional investor, and supports them in everything from their go-to-market strategy and the scaling of theirbusinesses. Cherry Ventures has previously invested in the seed stage of over 50 companies across Europe, including FlixBus, Auto1 Group, Infarm, Rows, Forto, and TourRadar. Cherry Ventures is based in Berlin and invests across Europe with operations in London, Paris, and Stockholm.
Show more...Investment focus
- Industry: Software, Information Technology, Financial Services
- Stage:Seed, Series A, Series B
- Geography: Germany, United Kingdom, United States
Investor stats
- Total investments: 290
- Round size: Seed $1.9M–$14M; Series A $7.3M–$44M; Series B $14M–$117M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fresh fund, raised $500M in 2025
Portfolio highlights
- Moss — Moss is a technology-based payment and credit card platform that enables companies to optimize their finances. Thanks to a dynamic and up to 10x higher limit, our corporate credit card can handle even the highest spend. With virtual and physical credit cards, the entire team can spend easily and securely. Individual spending limits and real-timedata per card, merchant or team keep costs under control. The Moss app makes it easy to digitize receipts, including cost center and VAT assignment. At the end of the month, all data and documents can be exported to any accounting software.
- Bits Technology — Bits Technology connects data sources & orchestrates workflows for financial tech services.
- Black Forest Labs — Official Account: https://t.co/iF047jr0Yg @bfl_ai
Entrepreneurs for Entrepreneurs
Show more...Investment focus
- Industry: Software, Information Technology, Automotive
- Stage:Seed, Series A, Series B
- Geography: Austria, Germany, Switzerland
Investor stats
- Total investments: 66
- Round size: Seed $540k–$1.2M; Series A $781k–$5.6M; Series B $4.2M–$13M
- Lead/follow: 77% lead, 23% follow
Portfolio highlights
- Diamens — Diamens is a company focused on femtech that develops a non-invasive menstrual blood-based molecular diagnostic to detect women-specific diseases like endometriosis.
- Respory — Respory provides real-time people-tracking using proprietary radar sensors, all without capturing personal data. Our scalable sensor network, powered by AI-driven algorithms, delivers precise customer journey insights, critical for in-store performance in retail.
- 2nd Cycle — 2nd Cycle creating a cost-effective, fully automated, and scalable solution for modules for a second life cycle.
SkyGene is a venture capital firm. The firm intends to invest in biotech firms.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Venture - Series Unknown
- Geography: Austria
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- VALANX Biotech — VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 142
- Round size: Seed $594k–$14M; Series A $1.7M–$40M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Esper — Esper is the first cloud-based platform to help governments proactively manage public policy with better data and transparency.
- Varda — Expanding the economic bounds of humankind with the world's first orbital manufacturing & reentry platform.
- TAG Therapeutics — TAG Therapeutics develops precision medicine approaches for telomere pathologies and aging-related diseases, such as Idiopathic Pulmonary Fibrosis and Short Telomere Syndromes
Investment Company
Show more...Investment focus
- Industry: Medical, Analytics, Health Diagnostics
- Stage:Seed, Series A
- Geography: Austria
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Medicus AI — Medicus AI is an innovative technology company that helps people understand their health by explaining their medical reports and health data to them in a personalized, easy-to-understand, and visual way.Through its consumer apps and enterprise software, Medicus is focused on bringing meaning to data, by helping patients and users understand theirhealth, and augmenting the roles of doctors, midwives, and other healthcare providers through innovative data visualization, patient communication, and remote monitoring tools.
A genetic medicines company developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Post-IPO Debt, Corporate Round, Post-IPO Equity
- Geography: United States, Austria, Denmark
Investor stats
- Total investments: 19
- Round size: Post-IPO Debt $15M–$85M; Corporate Round $3M–$10M; Post-IPO Equity $15M–$90M
- Lead/follow: 58% lead, 42% follow
Portfolio highlights
- Agenus — Activating the Power of the Immune System to Defeat Cancer
- Zerion Pharma — Zerion Pharma is a pharmaceutical company that aims to transform the pharmaceutical landscape with a new formulation technology. The company is focused on improving existing drugs by building an internal pipeline to solve the most challenging drug solubility problems that pharmaceutical companies face. Zerion Pharma was founded in 2019 and isbased in Birkerød, Denmark.
- Castle Creek Biosciences — Dedicated to making life better for people suffering from rare diseases with few or no treatment options
aws Gründerfonds is Austria's 70m venture capital fund. We invest as co-investor in Austrian high-growth start-ups in their later seed and (pre-)series-A stages.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Seed, Series A
- Geography: Austria, Germany, United States
Investor stats
- Total investments: 98
- Round size: Seed $1.3M–$5.2M; Series A $1.1M–$11M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely still investing — raised $77M in 2023
Portfolio highlights
- refinq — Asset-level climate and nature risk analytics for banks, insurers and corporates. Audit-ready data for CSRD, EU Taxonomy, EBA Pillar 3, SFDR and TNFD.
- vitrealab — Enlighten. Your perspective. Light Engines for AR glasses.
- Invisible-Light Labs — Invisible Light Labs uses Fourier transform infrared (FTIR) spectroscopy and nanoelectromechanical sensing technologies to enable chemical analysis of materials and nanomaterials that are available in minuscule amounts in a variety of industries, from environmental monitoring to pharmaceuticals.
bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Seed, Series A
- Geography: Germany, United States, Austria
Investor stats
- Total investments: 122
- Round size: Seed $165k–$3.6M; Series A $912k–$5.9M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely actively investing — fresh fund, raised $70M in 2024
Portfolio highlights
- Lab Thunder — LabThunder provides a cloud-based laboratory management software platform designed to digitize operational workflows. The system centers on centralizing equipment management, automated maintenance scheduling, digital logbooks, and AI-supported knowledge management to ensure audit-ready compliance.
- Sedivention — Fight obesity within 20 minutes - fast, effective, long-term. A new weight-loss therapy for the treatment of obesity. Just a view minutes will change your life.
- Solar Materials — Solar Materials primarily engages in the development of technologies for the sustainable and economical recycling of solar modules.
LANA Ventures is a venture capital firm.
Show more...Investment focus
- Industry: Health Care, Medical, Software
- Stage:Seed, Pre-Seed
- Geography: Austria, Germany
Investor stats
- Total investments: 4
- Round size: Seed $2.8M–$6.5M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- XUND — Answer the most important health questions with AI-powered technology from XUND. Medically certified and CE marked.
- UniteLabs — UniteLabs provides the foundational operating system for AI-driven lab automation in life science. It accelerates scientific discovery by closing the loop with a unified data and automation infrastructure, seamless integration, and intelligent control. Our platform empowers ambitious biotech companies, big pharma, integrators, and hardware vendorsby offering bidirectional connectors for diverse lab equipment, a scalable cloud platform with an open API, and a powerful workflow engine with an integrated compute environment. This allows for the creation of sophisticated, modular workflows, and enables rapid automation development through our Lab-as-Code environment, featuring a dynamic Python SDK and application-specific libraries.
- Aitiologic — A precision medicine startup providing multi-modal liquid biopsy solutions for early disease detection and targeted therapy.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!HV Capital is one of the leading early-stage and growth investors in Europe. With nine fund generations in 23 years and €2.8 bn in managed assets, HV Capital is one of the continent's most active investors. The investment team has many years of experience in identifying European startups with great potential for success. In addition tointernational success stories like Zalando, Delivery Hero, Sumup, and Depop, innovation leaders such as Enpal, Flixbus, Sennder, and Isar Aerospace are also part of the portfolio. HV Capital has invested in around 225 internet and technology companies, supporting startups with ticket sizes ranging from €0.5 to €60m. It is one of Europe's few venture capital firms that can finance startups through all growth phases. HV Capital has a team of more than 40 investment and operations professionals who provide a variety of perspectives and expertise across the venture capital landscape.
Show more...Investment focus
- Industry: E-Commerce, Software, Internet
- Stage:Series A, Seed, Series B
- Geography: Germany, United Kingdom, United States
Investor stats
- Total investments: 502
- Round size: Seed $1.5M–$12M; Series A $3.3M–$37M; Series B $7.7M–$80M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely still investing — raised $783M in 2023
Portfolio highlights
- Exein — Exein develops embedded cybersecurity solutions designed to secure Internet of Things (IoT) and connected devices. The company provides a platform that integrates security directly into the firmware of embedded systems, enabling real-time threat detection, monitoring, and response. Exein’s technology focuses on runtime protection and behavioranalysis at the edge, helping manufacturers secure devices without requiring major hardware changes or external software agents. Its solution is compatible with widely used real-time operating systems (RTOS) and Linux-based environments, allowing for flexible integration across different devices. The company also offers tools for vulnerability assessment and threat intelligence tailored for firmware-level defense. Exein supports developers with APIs and SDKs to incorporate security features during the product development phase. Through its platform, the company addresses growing security risks in critical sectors such as automotive, industrial automation, and consumer electronics.
- Flip — The AI employee experience platform for frontline workers without a company email. Flip unites comms, HR, identity and AI in one app. Book a demo.
- Ore Energy — Ore Energy is creating a new generation, cost effective, long-duration energy storage solution which will enable a decarbonized energy future by utilizing some of the most readily available materials
MMC is an early-stage venture capital fund investing in exceptional entrepreneurs across Europe.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 256
- Round size: Seed $1.4M–$9.8M; Series A $2.9M–$19M; Series B $10M–$54M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $129M in 2019
Portfolio highlights
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- ABEX — Algorithmic Best Execution for digital assets driven by an ultra low latency, high frequency, agency trading engine and enhanced by deep quantitative research.
- sable bio — We provide comprehensive, quantified, and flexible Target Safety Intelligence to assist toxicologists, informaticians, and drug discovery scientists in delivering safe and effective new treatments.
MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B, Seed
- Geography: Germany, France, Austria
Investor stats
- Total investments: 98
- Round size: Seed $1.3M–$13M; Series A $2.2M–$40M; Series B $1.7M–$60M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — raised $76M in 2014
Portfolio highlights
- NcodiN — The High Performance Computing (HPC) and ArtificiaI Intelligence (AI) era requires unprecedented computing capabilities. With this in view, industry is heading towards zettascale supercomputers, based on >100k processing units. Chiplets-based disaggregated processors and memory-centric computing architectures are taking over and require an ever more intensive communication between dies. Thus, today interconnect bottleneck is the main
- GlassPoint Solar — GlassPoint provides solar steam generators to the oil and gas industry for applications such as Enhanced Oil Recovery. It replaces gas-fired steam generation with solar, GlassPoint can reduce EOR gas consumption by up to 80 percent. The company was founded in 2008 and headquartered in Fremont, California.
- Zadient Technologies — Zadient produces semiconductor manufacturing materials that are critical for the entire silicon carbide (SiC) value chain
Investment Company
Show more...Investment focus
- Industry: Medical, Analytics, Health Diagnostics
- Stage:Seed, Series A
- Geography: Austria
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Medicus AI — Medicus AI is an innovative technology company that helps people understand their health by explaining their medical reports and health data to them in a personalized, easy-to-understand, and visual way.Through its consumer apps and enterprise software, Medicus is focused on bringing meaning to data, by helping patients and users understand theirhealth, and augmenting the roles of doctors, midwives, and other healthcare providers through innovative data visualization, patient communication, and remote monitoring tools.
Investor
Show more...Investment focus
- Industry: Medical, Analytics, Health Diagnostics
- Stage:Angel, Series A
- Geography: Austria
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Medicus AI — Medicus AI is an innovative technology company that helps people understand their health by explaining their medical reports and health data to them in a personalized, easy-to-understand, and visual way.Through its consumer apps and enterprise software, Medicus is focused on bringing meaning to data, by helping patients and users understand theirhealth, and augmenting the roles of doctors, midwives, and other healthcare providers through innovative data visualization, patient communication, and remote monitoring tools.
VP Venture Partners is a venture capital firm invests in healthcare companies.
Show more...Investment focus
- Industry: Medical, Health Diagnostics, Internet
- Stage:Seed
- Geography: Austria, Switzerland
Investor stats
- Total investments: 7
- Round size: Seed $3M–$6.9M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Diamens — Diamens is a company focused on femtech that develops a non-invasive menstrual blood-based molecular diagnostic to detect women-specific diseases like endometriosis.
- Moonlight AI — Moonlight AI was created to democratize the access to genomic information that is essential for therapy decision making in the era of personalized medicine.
- CollimateHealth — CollimateHealth is creating a clinically scalable microbeam radiation technology that will revolutionize the treatment of cancer.
Multi family office investing in proptech, digital health & sustainability
Show more...Investment focus
- Industry: Health Care, Medical, Health Diagnostics
- Stage:Seed, Series A, Pre-Seed
- Geography: Austria, Germany
Investor stats
- Total investments: 10
- Round size: Seed $165k–$658k; Series A $2.4M–$6.5M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Greenpass — Greenpass is an all-in-one SaaS for climate-resilient urban planning & architecture platform that enables livable cities.
- Kranus Health — Kranus Health is a global provider for Men‘s Health Prescription Digital Therapeutics (PDTs). Our therapies make millions of men live a better and longer life and enable doctors to treat their patients more efficiently.
- HelloBello — HelloBello offers freshly cooked and cooled delivered human-grade food tailored to each dog’s nutritional needs. HelloBello is a PetTech company with a strong focus on the German speaking markets (for now). HelloBello’s personalized meals are free of any by-products and are portioned, packaged, and delivered directly to your door. By working with aspecialized veterinarian, HelloBello is able to derive each dog’s exact nutritional needs based on a proprietary algorithm. The recipes are made of natural sources like millet and seaweed, instead of heavy use of supplements, which makes it easier for the dog to absorb and get true nutritional benefits.Our credo in German is " ... Frisch. Individuell. Geliefert. - Frischfutter ist einfach besser ..."
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Grant, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 125
- Round size: Grant $1.6M–$10M; Series C $10M–$127M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $331M in 2018
Portfolio highlights
- Lario Therapeutics — Lario Therapeutics are developing first-in-class disease modifying treatments for severe neurological disorders. Precision Neuroscience Today.
- Wysa — Use Wysa to vent or just talk through negative thoughts and emotions. Let it help you cope with pandemic anxiety and lockdowns. It is anonymous, safe and free.
- Ineffable Intelligence — Making first contact with superintelligence.
IBG Beteiligungsgesellschaft Sachsen-Anhalt is a venture capital firm makes investments in territories such as Germany and Denmark.
Show more...Investment focus
- Industry: Medical Device, Software, Electronics
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Germany, Austria
Investor stats
- Total investments: 20
- Round size: Seed $1.3M–$3M; Series A $4.3M–$13M
- Lead/follow: 15% lead, 85% follow
- Last fund: May invest from a new fund soon — raised $54M in 2017
Portfolio highlights
- RAYDIAX — We are Raydiax.Interventional only.Our goal is to reinvent computer tomography that is focussed on treatment.
- Solar Materials — Solar Materials primarily engages in the development of technologies for the sustainable and economical recycling of solar modules.
- PerioTrap Pharmaceuticals GmbH — PerioTrap is an early stage biopharmaceutical company that aims to eradicate the root cause of periodontitis
ARAX Capital Partners is an Austrian bio-tech and high-tech early stage investor with an exclusive focus on Austrian ventures. Companies need to be young, innovative (if possible with patentable technology) and must have already secured pre-seed funding to qualify for an investment
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Austria, United States
Investor stats
- Total investments: 10
- Round size: Seed $687k–$1.1M; Venture - Series Unknown $600k–$10M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $88M in 2008
Portfolio highlights
- Greenpass — Greenpass is an all-in-one SaaS for climate-resilient urban planning & architecture platform that enables livable cities.
- Calyxha Biotechnologies — A new perspective on inflammation
- EveliQure Biotechnologies GmbH — EveliQure was founded in 2012 with headquarters in Vienna and developed for the first time a combined vaccine, which is intended to protect against Shigella as well as against ETEC bacteria. Both bacterial strains cause various types of diarrheal diseases, and all attempts at development of vaccines have so far only aimed to protect against one ofthe two bacterial strains. The team led by Managing Director Gábor Somogyi has succeeded for the first time in producing a combined swallow vaccine that simultaneously protects against both bacterial strains.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investment Company
Show more...Investment focus
- Industry: Medical, Analytics, Health Diagnostics
- Stage:Series A
- Geography: Austria
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Medicus AI — Medicus AI is an innovative technology company that helps people understand their health by explaining their medical reports and health data to them in a personalized, easy-to-understand, and visual way.Through its consumer apps and enterprise software, Medicus is focused on bringing meaning to data, by helping patients and users understand theirhealth, and augmenting the roles of doctors, midwives, and other healthcare providers through innovative data visualization, patient communication, and remote monitoring tools.
EMBL Ventures is a German venture capital engaged in the financing and development of products and technologies in the healthcare sector. EMBL Ventures manages three Funds with a total of 120m capital on behalf of major European private and institutional investors. We prefer a role as lead or co-lead investor in financing rounds which typicallyrange from 5m to 40m. Our total commitment in a single portfolio company can go as high as 10m. As with our portfolio companies each Partner at EMBL Ventures strives to build long-lasting personal relationships with Investors in our Funds, such as institutionals, high net-worth individuals and family offices. These relationships are based on EMBL Ventures' core values of open and prompt communication coupled with the ambition to generate maximum return.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Germany, Austria, Ireland
Investor stats
- Total investments: 13
- Round size: Series A $3.9M–$16M; Series B $21M–$70M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $54M in 2011
Portfolio highlights
- Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
- Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
IPO Beteiligungs-Management is a private equity company specialized in early stage venture investments.
Show more...Investment focus
- Industry: Sensor, Medical, Wireless
- Stage:Series B
- Geography: Austria
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- SensorDynamics — SensorDynamics was a European semiconductor and MEMS company specialized in developing and manufacturing high-volume micro- and wireless semiconductor sensor products for applications in automotive, industry and high-end consumer sectors. The company was acquired by Maxim Integrated in 2011 for $164 million. SensorDynamics developed and producedcustom-made designs and standard components for use in vehicle stabilization, occupant protection, navigation systems, keyless go systems and autonomous energy generators for wireless and battery free controllers for industrial, automotive and high-end consumer application.[5] With its headquarters in Graz, Austria, SensorDynamics had offices in Italy and Germany and a worldwide sales and distribution network. The company employed about 130 people in 2011.
- EUCODIS Bioscience — EUCODIS Bioscience is an experienced enzyme engineering company, providing industrial customers with high-performing enzymes. Their customers are leaders in the chemical, the pharmaceutical, the food and feed and cosmetics industries.
We back B2B software and life-sciences companies with limitless scalability.
Show more...Investment focus
- Industry: Software, Biotechnology, Telecommunications
- Stage:Seed, Pre-Seed
- Geography: Austria, Germany
Investor stats
- Total investments: 10
- Round size: Seed $1.8M–$4.4M
- Lead/follow: 80% lead, 20% follow
Portfolio highlights
- Txture — IBM Consulting uses IBM Txture to help organizations assess application portfolios, plan cloud modernization and build data-driven transformation strategies.
- HeartBeat.bio — HeartBeat.bio is a privately funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies.
- MAVOCO — We create a carrier-grade software for IoT champions, trusted by tier-1 Mobile network operators.
FCPG Affi
Show more...Investment focus
- Industry: Medical, Biotechnology, Pharmaceutical
- Stage:Venture - Series Unknown
- Geography: Austria
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- AFFiRiS — AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 107
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
- TECregen — TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 230
- Round size: Series A $5.1M–$85M; Series B $11M–$120M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Visiogen — Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions.The device isdesigned to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
- Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
- Rein Therapeutics — Rein Therapeutics is advancing a novel pipeline of first-in-class medicines to address unmet medical needs in orphan pulmonary and fibrosis indications.
redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: Germany, Switzerland, United Kingdom
Investor stats
- Total investments: 181
- Round size: Seed $1.6M–$12M; Series A $3.2M–$31M; Series B $15M–$59M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $25M in 2013
Portfolio highlights
- Umiami — Umiami Technologies is a leader in plant-based meat. Our proprietary technology allows us to create clean-label and incredibly tasty foods.
- Albatross AI — Inspire Customers Boost Conversions Capture Missed Revenues
- Hypervision Surgical — Making surgeries more precise, safer and faster. Guiding the future of surgery using AI-powered hyperspectral imaging.
Santo Holding is a Zurich-based investment firm funding biotechnology, pharmaceutical, life sciences, and healthcare companies.
Show more...Investment focus
- Industry: Biotechnology, Energy, Medical
- Stage:Venture - Series Unknown, Series B, Series C
- Geography: Germany, Austria
Investor stats
- Total investments: 6
- Round size: Venture - Series Unknown $7.7M–$10M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- AFFiRiS — AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions.
- SuppreMol — SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.
- Efficient Energy — Efficient Energy GmbH is an innovative manufacturer and system supplier of environmentally friendly refrigeration technology, based in Feldkirchen near Munich, Germany. The company developed the Bluezero-technology, which uses water as a refrigerant and and thereby entirely avoids fluorinated refrigerants (HFCs). Efficient Energy helps itscustomers overcome the increasing regulatory challenges of refrigeration technology, and offers them long-term, sustainable solutions with its eChiller model range. The eChiller chilled water units are ideally suited for process cooling, machine cooling and the cooling of technical equipment and data centres and provide cooling capacities from 35 kW to 120 kW, depending on the model. With its outstanding cost efficiency and low CO2 footprint, companies benefit on many fronts. The pioneering technology has also been noticed by politics and the media, and has received multiple awards for the eChiller. These include among others the European Business Award for the Environment 2018/2019 from the European Comission and the Red Herring Europe Top 100 in 2020.
Biopart
Show more...Investment focus
- Industry: Medical, Analytics, Health Diagnostics
- Stage:Series A
- Geography: Austria
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Medicus AI — Medicus AI is an innovative technology company that helps people understand their health by explaining their medical reports and health data to them in a personalized, easy-to-understand, and visual way.Through its consumer apps and enterprise software, Medicus is focused on bringing meaning to data, by helping patients and users understand theirhealth, and augmenting the roles of doctors, midwives, and other healthcare providers through innovative data visualization, patient communication, and remote monitoring tools.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.The company operates through three segments: BioScience, Medication Delivery, and Renal.- The BioScience segment manufacturesrecombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products and technologies used in adult stem-cell therapies; and vaccines.- The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs, intravenous nutrition products; infusion pumps; and inhalation anesthetics. This segment also offers products and services related to pharmacy compounding, drug formulation, and packaging technologies.- The Renal segment provides products to treat end-stage renal disease and irreversible kidney failure. This segment also offers solutions and other products for peritoneal dialysis, a home-based therapy and product for hemodialysis, which is conducted in a hospital or clinic.Baxter International Inc. has collaborations with HHD LLC, DEKA Products Limited Partnership, and DEKA Research and Development Corp. for the development of a home hemodialysis machine. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, clinical and medical research laboratories, and patients at home under physician supervision.The company was founded in 1931 and is headquartered in Deerfield, Illinois.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series B, Series C
- Geography: United States, Canada, Austria
Investor stats
- Total investments: 9
- Round size: Seed $238k–$1.5M; Series C $3.3M–$25M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- NovaXS Biotech — NovaXS Biotech powering accessible healthcare for all.A smart drug delivery platform that administers a narrow stream of medication without a needle.
- Walela — Whether your company distributes prenatal monitoring software or you are a clinical researcher that wants to get involved, we would love to connect.
- Medically Home — Medically Home is a tech-enabled clinical enterprise that provides all the necessary capabilities to safely-shift medical care from hospitals to patients’ homes. Its platform offers a virtual hospital program that connects patients with caregivers and supports the monitoring of, and communication with patients with high acuity illness that helppatients and their families to access a medical command center that provides centralized, on-demand acute medical care management from the comfort of their homes.The company was founded in 2016 and is headquartered in Boston, Massachusetts.
We invest in B2B tech entrepreneurs who are obsessed with solving complex problems in huge markets at pre-seed and seed stage
Show more...Investment focus
- Industry: Software, SaaS, E-Commerce
- Stage:Seed, Series A
- Geography: Germany, United States, Poland
Investor stats
- Total investments: 76
- Round size: Seed $329k–$5.3M; Series A $2.9M–$17M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $117M in 2022
Portfolio highlights
- Hero — Hero is a B2B payments and financing platform, offer direct online payment experience and receive your money immediately.
- Otterspace — Otterspace is an NFT company that aims to use earned NFTs rather than purchased NFTs to reward and recognize participation in decentralized autonomous organizations (DAOs). Its non-transferable badge protocol assists DAOs in developing more effective incentive systems, automating permissions, and enabling non-financialized governance.
- Flinn — We are driven to impact the health of millions of people around the globe by enabling medical companies to launch and operate products more efficiently. To make this vision come true, we established a customer-centric, experimentation-driven product development approach.
IT-Farm is a venture capital firm which specializes in seed, start-up, and early stage companies. It primarily invests in mobile, big-data, connected car, IoT, OTT service, Helth care, Bio Tech and other IT industries. The firm actively invests in SF bay area and Japan, as well as other geometries including Asia and Europe. We support portfoliocompanies, especially on the partnership with Japanese enterprises.
Show more...Investment focus
- Industry: Software, Health Care, Medical
- Stage:Seed, Series A
- Geography: United States, Japan, Germany
Investor stats
- Total investments: 120
- Round size: Seed $1.8M–$9.3M; Series A $1.8M–$20M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- BitBiome — BitBiome is a microbiome analysis company that aims to discover and understand disease-linked microorganisms. Its, single-cell whole-genome analysis platform specifically targets microbes and can be used on uncultured, raw samples, providing unprecedented strain-level quantitative and functional insights.THe company was founded in 2018 and isbased in Japan.
- TopoLogic — TopoLogic designs and manufactures heat flow sensors, thermoelectric conversion devices, and topological and novel spintronics materials.
- Global Equipment Services — As a strategic partner to developers of multi-sector products, Averna provides innovative automated testing tool and quality assurance solutions.
Identifying opportunities for investors and providing capital for cutting-edge innovations in the oral and systemic health sectors.
Show more...Investment focus
- Industry: Health Care, Dental, Medical
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, The Netherlands, Austria
Investor stats
- Total investments: 15
- Round size: Seed $1M–$4.5M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- OrisDX — OrisDX is a saliva based diagnostics company detecting and fighting cancer.
- AugmedIT B.V. — Augmedit offers medical software that guides doctors through complicated surgeries with the help of augmented reality
- Entirety Biomedical — High Performance Absorbable Implants
Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 99
- Round size: Series A $4.7M–$22M; Series B $5.2M–$44M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Streaming21 — Streaming21 is a solution provider of seamless on-demand and IP broadcasting service platform for connected digital home.
- Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
- Precision Therapeutics — Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.
MMV is a multistage, global venture capital firm investing in enterprise software, cybersecurity, financial technology, and digital health companies. We help accelerate the growth of the companies we partner with by providing capital, connections and advice.
Show more...Investment focus
- Industry: Financial Services, FinTech, Health Care
- Stage:Series A, Seed, Series B
- Geography: Singapore, India, United States
Investor stats
- Total investments: 33
- Round size: Seed $2.4M–$7.5M; Series A $4M–$15M; Series B $20M–$65M
- Lead/follow: 58% lead, 42% follow
- Last fund: May invest from a new fund soon — raised $100M in 2020
Portfolio highlights
- Sikoia — Streamline your decision-making with centralized customer data, comprehensive case management, and automated risk evaluation without complicated integrations.
- Fund That Flip — Fund That Flip offers customized lending for real estate investors. Partner with America's fastest-growing direct lender. Better than your hard money lender.
- Scrut Automation — Scrut Automation makes ISO 27001, SOC 2, GDPR and PCI DSS compliance easy, with 70% less Manual effort
We are i&i Biotech Fund, partners of outstanding founders on their path to global success. We invest in innovative early stage Life Sciences startups.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: Czech Republic, India, Spain
Investor stats
- Total investments: 10
- Lead/follow: no public data
Portfolio highlights
- Antiverse — Designing biologics for 100 challenging targets
- Captain T Cell — Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients. The company identifies novel high-efficiency TCRs for the development of T cell immunotherapies. It focuses on CMC- and preclinical development for their lead candidates.
- Casinvent Pharma — Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies.
TBA Network provides risk capital, entrepreneurial expertise, and valuable network support to ambitious founders. TBA objective is to support innovative ideas and contribute to the global expansion of early-stage startups, laying the groundwork for future entrepreneurs.
Show more...Investment focus
- Industry: Apps, Medical, mHealth
- Stage:Seed
- Geography: Austria, Italy
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- XUND — Answer the most important health questions with AI-powered technology from XUND. Medically certified and CE marked.
- Tree.ly — Tree.ly does climate protection through the projects in European forests through its SaaS platform and hyperlocal CO2-credits.
- ALLSIDES — Covision Media specializes in creating high-quality, relightable 3D models using their industrial 3D scanners. These scanners capture detailed surface information and PBR textures, and are designed for easy integration into virtual environments.
Lead Ventures is a Budapest-based venture capital firm, specialist of financing scale-ups in Central Europe. Its mission is to support the region’s most promising ventures with capital, experience and a wide-ranging professional network, enabling them to transform their industry with innovation. Lead Ventures provides equity financing tocompanies in their scale-up phase, the typical ticket size is between EUR 2-10 million. Lead Ventures is searching for dynamic teams with a unique story, outstanding growth potential and solutions tested and validated by the market. The firm seeks to invest in companies operating in the mobility, energy and sustainability as well as b2b services and software sectors, however, Lead Ventures is open to support teams active in other areas as well.Lead Ventures has EUR 200 million under management invested by MOL, the most successful energy company in CEE, and two financial institutions specialised in supporting the startup ecosystem - the Hungarian Development Bank (MFB) and Eximbank.
Show more...Investment focus
- Industry: Software, SaaS, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: Hungary, United Kingdom, Croatia
Investor stats
- Total investments: 27
- Lead/follow: no public data
Portfolio highlights
- Oxla — Meet Oxla, the world's fastest-distributed database, designed to handle large amounts of data with ease.
- XUND — Answer the most important health questions with AI-powered technology from XUND. Medically certified and CE marked.
- RedTrack.io — RedTrack.io offers real-time access to your media buying KPIs/data: ad tracking, impressions, clicks, conversions across multiple channels & 30 data points.
New generation venture capital investing into combinatorial technologies
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Machine Learning
- Stage:Pre-Seed, Seed
- Geography: Czech Republic, United States, United Kingdom
Investor stats
- Total investments: 19
- Lead/follow: no public data
Portfolio highlights
- Wultra — Wultra helps the leading banks and fintech companies to secure their digital systems and bring trust to the customer journeys. Our security-related software technologies cover the whole digital banking application stack, be it on the web or mobile platforms.
- Openvibe — Interact With Anyone On The Open Internet. All Decentralised Social Networks, Single Timeline.
- Edmund — Edmund is an enterprise level system that interconnects all manufacturing technologies, providing a comprehensive view of entire factory.
Medical VC funding in Austria at a glance
Stats across 88 deals from 113 investors.
Access all 113 VC funds in Austria Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical VC Funds in Austria investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 113 VC funds investing in Austria Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!